company background image
MPH

Medicure TSXV:MPH Stock Report

Last Price

CA$1.37

Market Cap

CA$14.0m

7D

44.2%

1Y

24.5%

Updated

18 Aug, 2022

Data

Company Financials
MPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

MPH Stock Overview

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States.

Medicure Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medicure
Historical stock prices
Current Share PriceCA$1.37
52 Week HighCA$1.50
52 Week LowCA$0.80
Beta0.88
1 Month Change52.22%
3 Month Change9.60%
1 Year Change24.55%
3 Year Change-70.22%
5 Year Change-82.44%
Change since IPO-87.32%

Recent News & Updates

Shareholder Returns

MPHCA BiotechsCA Market
7D44.2%1.0%1.3%
1Y24.5%16.5%3.3%

Return vs Industry: MPH exceeded the Canadian Biotechs industry which returned 14.1% over the past year.

Return vs Market: MPH exceeded the Canadian Market which returned 2.1% over the past year.

Price Volatility

Is MPH's price volatile compared to industry and market?
MPH volatility
MPH Average Weekly Movementn/a
Biotechs Industry Average Movement13.1%
Market Average Movement10.5%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.2%

Stable Share Price: Insufficient data to determine MPH's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine MPH's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aAlbert Friesenhttps://www.medicure.com

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.

Medicure Fundamentals Summary

How do Medicure's earnings and revenue compare to its market cap?
MPH fundamental statistics
Market CapCA$14.04m
Earnings (TTM)CA$803.00k
Revenue (TTM)CA$22.52m

17.5x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MPH income statement (TTM)
RevenueCA$22.52m
Cost of RevenueCA$8.80m
Gross ProfitCA$13.73m
Other ExpensesCA$12.93m
EarningsCA$803.00k

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 24, 2022

Earnings per share (EPS)0.078
Gross Margin60.95%
Net Profit Margin3.57%
Debt/Equity Ratio0%

How did MPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MPH?

Other financial metrics that can be useful for relative valuation.

MPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.5x
Enterprise Value/EBITDA8x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does MPH's PE Ratio compare to its peers?

MPH PE Ratio vs Peers
The above table shows the PE ratio for MPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average8.5x
IBT IBEX Technologies
7.4xn/aCA$12.3m
APC Advanced Proteome Therapeutics
4.5xn/aCA$5.8m
MBX Microbix Biosystems
24x29.4%CA$72.8m
WLLW Willow Biosciences
n/an/aCA$14.2m
MPH Medicure
17.5xn/aCA$14.0m

Price-To-Earnings vs Peers: MPH is expensive based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (8.5x).


Price to Earnings Ratio vs Industry

How does MPH's PE Ratio compare vs other companies in the North American Biotechs Industry?

Price-To-Earnings vs Industry: MPH is expensive based on its Price-To-Earnings Ratio (17.5x) compared to the North American Biotechs industry average (16x)


Price to Earnings Ratio vs Fair Ratio

What is MPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MPH's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MPH's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Medicure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Medicure's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Medicure competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Medicure performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-47.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MPH has a large one-off gain of CA$2.1M impacting its March 31 2022 financial results.

Growing Profit Margin: MPH became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MPH has become profitable over the past 5 years, growing earnings by -47.2% per year.

Accelerating Growth: MPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: MPH's Return on Equity (4.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Medicure's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MPH's short term assets (CA$13.0M) exceed its short term liabilities (CA$8.1M).

Long Term Liabilities: MPH's short term assets (CA$13.0M) exceed its long term liabilities (CA$1.4M).


Debt to Equity History and Analysis

Debt Level: MPH is debt free.

Reducing Debt: MPH has no debt compared to 5 years ago when its debt to equity ratio was 187.5%.

Debt Coverage: MPH has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MPH has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Medicure current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Albert Friesen (75 yo)

no data

Tenure

CA$302,063

Compensation

Dr. Albert David Friesen, Ph.D. serves as Chief Executive Officer and Corporate Secretary and Director at Buffalo Capital Inc. Dr. Friesen serves as Chief Executive Officer at Canam Bioresearch Inc. Dr. Fr...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD233.81K) is about average for companies of similar size in the Canadian market ($USD185.51K).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MPH's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: MPH's board of directors are seasoned and experienced ( 17.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medicure Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Medicure Inc.
  • Ticker: MPH
  • Exchange: TSXV
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$14.044m
  • Shares outstanding: 10.25m
  • Website: https://www.medicure.com

Location

  • Medicure Inc.
  • 2-1250 Waverley Street
  • Winnipeg
  • Manitoba
  • R3T 6C6
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/18 00:00
End of Day Share Price2022/08/18 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.